[1] Blumhardt R, Wolin E A, Phillips W T, et al. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review [J]. Endocr Relat Cancer, 2014, 21(6): 473-484. [2] Piruzan E, Haghighatfshar M, Faghihi R, et al. Calculation of blood dose in patients treated with 131I using MIRD, imaging, and blood sampling methods [J]. Medicine (Baltimore), 2016, 95(11): e3154. [3] 核工业标准化研究所. 电离辐射防护与辐射源安全基本标准:GB 18871—2002[S]. 北京: 中国标准出版社,2002. Institute for Standardization of Nuclear Industry. Basic standards for protection against ionizing radiation and for the safety of radiation sources: GB 18871—2002[S]. Beijing: China Standards Press,2002. [4] Steward P G. An excel-based system to manage radiation safety for the family of patients undergoing 131I therapy [J]. J Nucl Med Technol, 2017, 45(2):102-110. [5] Alessio D, Giliberti C, Benassi M, et al. Potentional third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases [J]. Health Phys, 2015, 108(3): 319-325. [6] IAEA. Nuclear medicine resources manual [M]. Vienna: International Atomic Energy Agency, 2006. [7] 中国疾病预防控制中心辐射防护与核安全研究所. 临床核医学放射卫生防护标准:GBZ 120—2006 [S]. 北京:人民卫生出版社,2007. National Institute for Radiological Protection, China CDC. Radiological protection standards for clinical nuclear medicine: GBZ 120—2006 [S]. Beijing: People’s Medical Publishing House, 2007. [8] Ahmadi Jeshvaghane N, Paydar R, Fasaei B, et al. Criteria for patient release according to external dose rate and residual activity in patients treated with 131I-sodium iodide in Iran[J]. Radiat Prot Dosimetry, 2011,147(1-2):264-266. [9] Vallejo Casas J A, Mena Bares L M, Gálvez M A, et al. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods [J]. Nucl Med Commun,2011,32(9):840-846. [10] Nicol A, Robertson J, McCurrach A. Practical matters for the control of contamination in a nuclear medicine department[J]. J Radiol Prot, 2011,31(1):141-146. [11] Culver C M, Dworkin H J. Radiation safety considerations for post-iodine-131 thyroid cancer therapy [J]. J Nucl Med, 1992,33(7): 1 402-1 405. [12] Fofi C, Festuccua F, Barberi S, et al. Hemodualysis in patients requiring 131I treatment for thyroid carcinoma [J]. Int H Artif Organs, 2013, 36(6): 439-543. [13] ICRP. The 2007 recommendations of the international commission on radiological protection [M]. ICRP publication 103. Elsevier, 2007. [14] ICRP. Conversion coefficients for use in radiological protection against external radiation[M]. ICRP publication 74. Oxford: Pergamon Press, 1995. [15] Zankl M. Personal dose equivalent for photons and its variation with dosimeter position [J]. Health Phys, 1999, 76(2):162-170. [16] Stadtmann H. Dose quantities in radiation protection and dosimeter calibration[J]. Radiat Prot Dosimetry, 2001, 96 (1-3): 21-26. [17] Endo A. On behalf of ICRU report committee 26 on operational radiation protection quantities for external radiation: Operational quantities and new approach by ICRU [J]. Ann ICRP, 2016, 45 (1 Suppl): 178-187. [18] Sudbrock F. Fischer T, Zimmermanns B, et al. Exhalation of 131I after radioiodine therapy: Dosimetric considerations based on measurements in exhaled air[J]. J Environ Radioact, 2017, 166(Pt1): 162-165. |